ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2025
The Breast Tumor Immune Microenvironment of DNA Double-Strand Break Repair Pathogenic Variant Carriers Is Enriched with Tumor-Associated Macrophages.
Rebecca L Kelly, Yuxi Liu, Alexandra R Harris, Cheng Peng, Yujing J Heng, Gabrielle M Baker, Daniel G Stover, Rulla M Tamimi, Peter Kraft
Abstract read
In one paragraphArticle in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from itWhat it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
9 authors.
Rebecca L KellyCancer Prevention Fellowship Program, National Cancer Institute, Rockville, Maryland.ORCID 0009-0009-4378-737X Yuxi LiuDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.ORCID 0000-0003-2484-151X Alexandra R HarrisCancer Prevention Fellowship Program, National Cancer Institute, Rockville, Maryland.ORCID 0000-0002-1049-3131 Cheng PengChanning Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.ORCID 0000-0002-0220-5128 Yujing J HengDepartment of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.ORCID 0000-0002-8930-817X Gabrielle M BakerDepartment of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.ORCID 0000-0002-9213-0317 Daniel G StoverDivision of Medical Oncology, Stefanie Spielman Comprehensive Breast Center, Ohio State University Comprehensive Cancer Center, Columbus, Ohio.ORCID 0000-0001-9003-8165 Peter KraftDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.ORCID 0000-0002-4472-8103 Funding
Statistical MethodsP01CA087969 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI ELIASSEN, A. HEATHER, TAMIMI, RULLA M · 2000 to 2019
$77.8MRisk Factors for Breast Cancer in Younger NursesR01CA050385 · NCI · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI ELIASSEN, A. HEATHER, WILLETT, WALTER C. · 1989 to 2019
$32.3MLife Course Cancer Epidemiology Cohort in WomenU01CA176726 · NCI · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI ELIASSEN, A. HEATHER, WILLETT, WALTER C. · 2018 to 2025
$22.4MLong Term Multidisciplinary Study of Cancer in Women: The Nurses Health StudyUM1CA186107 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI ELIASSEN, A. HEATHER, STAMPFER, MEIR · 2014 to 2023
$22.3MPremonopausal Hormone Levels and Risk of Breast CancerR01CA067262 · NCI · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI HANKINSON, SUSAN E · 2002 to 2011
$11.9MBIOCHEMICAL MARKERS IN THE NURSES'HEALTH STUDY COHORTR01CA049449 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI HANKINSON, SUSAN E · 1989 to 2008
$11.3MEpidemiologic StudiesU19CA148065 · NCI · HARVARD SCHOOL OF PUBLIC HEALTH · PI AHSAN, HABIBUL, BRUGGE, JOAN SIEFERT · 2010 to 2014
$10.6MBIOCHEMICAL MARKERS IN THE NURSES HEALTH STUDY COHORTU01CA049449 · NCI · UNIVERSITY OF MASSACHUSETTS AMHERST · PI HANKINSON, SUSAN E · 1995 to 2013
$5.4MAssessing the role of androgens in breast cancer riskR01CA166666 · NCI · UNIVERSITY OF MASSACHUSETTS AMHERST · PI HANKINSON, SUSAN E · 2012 to 2015
$1.7MPrediagnostic exposures, germline genetics, and triple negative breast cancer mutational and immune profilesR01CA260352 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI KRAFT, PETER, TAMIMI, RULLA M · 2021 to 2022
$1.3MDivision of Cancer Prevention, National Cancer Institute (DCP, NCI)National Cancer Institute (NCI) P01CA087969National Cancer Institute (NCI) R01CA166666National Cancer Institute (NCI) R01CA260352National Cancer Institute (NCI) R01CA49449National Cancer Institute (NCI) R01CA50385National Cancer Institute (NCI) R01CA67262National Cancer Institute (NCI) U01CA176726National Cancer Institute (NCI) U19CA148065National Cancer Institute (NCI) UM1CA186107NCI NIH HHS P01 CA087969NCI NIH HHS R01 CA049449NCI NIH HHS R01 CA050385NCI NIH HHS R01 CA067262NCI NIH HHS R01 CA166666NCI NIH HHS R01 CA260352NCI NIH HHS U01 CA049449NCI NIH HHS U01 CA176726NCI NIH HHS U19 CA148065NCI NIH HHS UM1 CA186107
6 · The paper itselfAbstract
backgroundApproximately 5% of patients with breast cancer have a rare pathogenic germline genetic variant that is associated with increased breast cancer risk. Mutations in more than 12 genes have been associated with hereditary breast cancer risk, many of which are involved in genome stability pathways, including DNA double-strand break (DSB) repair. We hypothesized that carriers of DSB repair-related pathogenic variants (PV) may have a distinct tumor immune environment that differs from that of noncarriers.
methodsWe utilized tumor transcriptome data from 559 participants with invasive breast cancer from the Nurses' Health Studies and Nurses' Health Studies II to infer immune-related gene expression signatures and immune cell abundance.
resultsThirty-three (5.9%) individuals had germline DSB repair-related PVs in one or more of the following genes: ATM, BARD1, BLM, BRCA1, BRCA2, BRIP1, CHEK2, FANCC, FANCM, NBN, PALB2, RAD50, RAD51C, and/or RECQL. In covariate-adjusted analyses, DSB repair-related PV carrier status was positively associated with both a STAT1 signature (standardized β = 0.59; P = 3.5 × 10-3) and inferred M1 macrophage infiltration (standardized β = 0.56; P = 1.4 × 10-3). Furthermore, these immune features correlated with other features related to tumor IFN response signaling, suggesting that this enrichment is occurring in an inflammatory context.
conclusionsThese results indicate that breast tumors of DSB repair-related PV carriers have distinct immune features, which may have therapeutic implications in this high-risk population. IMPACT: These results support further characterization of macrophage characteristics and abundance in the breast tumor microenvironment of DSB repair-related PV carriers.
Indexed as
Breast NeoplasmsDNA Breaks, Double-StrandedDNA RepairTumor-Associated MacrophagesTumor MicroenvironmentAdultFemaleGenetic Predisposition to DiseaseGerm-Line MutationHumansMiddle Aged
Identifiers
PMID40172573
PMCPMC12374719
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390